WO2000074696A1 - Combination of glucosamine with herbal extracts of tripterygium, ligustrum and erycibe - Google Patents
Combination of glucosamine with herbal extracts of tripterygium, ligustrum and erycibe Download PDFInfo
- Publication number
- WO2000074696A1 WO2000074696A1 PCT/GB2000/002092 GB0002092W WO0074696A1 WO 2000074696 A1 WO2000074696 A1 WO 2000074696A1 GB 0002092 W GB0002092 W GB 0002092W WO 0074696 A1 WO0074696 A1 WO 0074696A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glucosamine
- composition according
- formulated
- herbal composition
- per
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Definitions
- the present invention relates to herbal formulations comprising glucosamine and Chinese herbs which can be administered to humans and animals as dietary supplements and as pharmaceutical dosage forms to alleviate the symptoms of arthritis.
- Glucosamine increases the ability of cartilage to synthesize both sulphated mucopolysaccharides and protein in a dose-dependent way, thus restoring the degradation- synthesis balance of cartilage.
- Glucosamine increases the ability of cartilage to synthesize both sulphated mucopolysaccharides and protein in a dose-dependent way, thus restoring the degradation- synthesis balance of cartilage.
- the symptoms of pain at rest- on standing, on exercise and during limited active and passive movements improved steadily through the treatment period. The improvement obtained lasted for a period of six to twelve weeks after the end of treatment.
- Objective therapeutic efficacy was rated by the doctors as good in 59% of patients, and sufficient in an additional 36% of patients.
- Oral glucosamine sulphate in the management of arthritis report on a multi-center open investigation in Portugal, 3 PHAlUviATj?ffiRAPET ⁇ cA.157-168 (1982). Oral glucosamine was fully tolerated by 86% of patients, a significantly larger proportion than that reported with other treatments and approached only by injectable glucosamine.
- glucosamine is available in America and European countries as a dietary supplement in the form of tablets, capsules and chewable bars containing pharmaceutical grade glucosamine.
- pure commercial glucosamine products are available containing glucosamine sulphate in 500 mg capsules or in 750 mg capsules.
- Combinations of glucosamine with herbs, vitamins and minerals are also available; an example of a commercially available product contains glucosamine (300 mg), chondroitin sulfate, ginger, white willow, boswellia, curcumin, vitamin C, zinc, manganese, and selenium.
- Other formulations of glucosamine include those described in U.S. Patent 5,679,344 to
- glucosamine While glucosamine is generally accepted as being effective and safe for treating osteoarthritis, medical intervention into the treatment of this degenerative joint diseases is generally restricted to the alleviation of its acute symptoms.
- Medical practitioners generally use nonsteroidal and steroidal anti-inflammatory drugs for treatment of osteoarthritis. These drugs, however, are not well-adapted for long-term therapy because they not only lack the ability to promote and protect cartilage, they can actually lead to degeneration of cartilage or reduction of its synthesis. Moreover, most nonsteroidal anti-inflammatory drugs damage the gastrointestinal system when used for extended periods of time. Thus, new treatments for arthritis are urgently needed.
- glucosamine The joint-protective properties of glucosamine would make it an attractive therapeutic agent for arthritis except for two drawbacks: (i) the rate of response to glucosamine treatment is slower than for treatment with anti-inflammatory drugs, and (ii) glucosamine may fail to fulfill the expectation of degenerative remission.
- studies comparing glucosamine with nonsteroidal anti-inflammatory agents for example, a double-blinded study comparing 1500 mg glucosamine sulfate per day with 1200 mg ibuprofen demonstrated that pain scores decreased faster during the first two weeks in the ibuprofen patients than in the glucosamine- treated patients.
- glucosamine may relieve the pain and inflammation of arthritis at a slower rate than the available anti- inflammatory drugs.
- An ideal formulation for the normalization of cartilage metabolism or treatment of osteoarthritis would combine adequate chondroprotection with potent anti-inflammatory activity.
- the optimal formulation for arthritis should enhance the general joint rebuilding qualities offered by glucosamine and attenuate the inflammatory response without introducing any harmful side effects.
- the formulation should be inexpensively manufactured and comply with all governmental regulations.
- the present invention provides a herbal composition which comprises glucosamine and at least one herb selected from Tripterygium wilfordii, Ligustrum lucidum and Erycibe schmidtii.
- Tripterygium wilfordii Ligustrum lucidum and Erycibe schmidtii are Chinese herbs that have been used for their anti-inflammatory properties.
- Tripterygium wilfordii can be toxic when used in high amounts. It has surprisingly been found that, when incorporated into the herbal composition of the present invention, its anti-inflammatory effect is enhanced to the extent that it can be used at sufficiently low doses to avoid adverse side effects.
- the herbal composition of the invention comprises glucosamine and each of Tripterygium wilfordii, Ligustrum lucidum and Erycibe schmidtii.
- the herbal composition comprises synergistically effective amounts of the glucosamine and the or each said herb.
- the invention therefore also provides the use of glucosamine as a synergist in a herbal composition which comprises at least one Chinese herb selected from Tripterygium wilfordii, Ligustrum lucidum and Erycibe schmidtii.
- the invention further provides the use of at least one Chinese herb selected from Tripterygium wilfordii, Ligustrum lucidum and Erycibe schmidtii as a synergist in a herbal composition which comprises glucosamine.
- the herbal composition preferably further comprises one or both of the other two said Chinese herbs.
- the present invention also provides a pharmaceutical or veterinary composition that comprises a pharmaceutically or veterinarily effective amount of a herbal composition of the invention as defined above and a pharmaceutically or veterinarily acceptable carrier or diluent.
- the invention further provides a dietary composition, such as a dietary supplement, which comprises a herbal composition of the invention as defined above and a dietetically acceptable carrier or diluent.
- the present invention further provides a method of dietary supplementation which comprises the administration to a human or animal suffering symptoms of an ailment which involves the inflammation or degeneration of joint tissues, such as arthritis, a herbal composition of the invention as defined above and continuing such administration of the composition until said symptoms are reduced.
- the present invention also provides the use of glucosamine and at least one herb selected from Tripterygium wilfordii, Ligustrum lucidum and Erycibe schmidtii in the manufacture of a medicament for the treatment of symptoms of an ailment which involves the inflammation or degeneration of joint tissues, such as arthritis.
- a human or animal patient may thus be treated by a method which comprises the administration thereto of a pharmaceutical or veterinary composition of the invention as defined above.
- the symptoms of arthritis and other joint ailments which involve inflammation and/or degeneration of joint tissues are thereby alleviated.
- compositions enhance the synthesis of glucosaminoglycans and hyaluronic acid while reducing the inflammatory response, thereby promoting both the rebuilding and healing of affected joints.
- Figure 1 provides a scheme which illustrates the cycle of tissue destruction and inflammation in osteoarthritis and how the components of the present formulation may modulate this cycle.
- glucosamine can diminish tissue destruction;
- Ligustrum lucidum can inhibit COX-2 enzyme activity;
- Tripterygium wilfordii can inhibit the expression of COX-2 mRNA;
- Erycibe schmidtii can inhibit inflammation and relieve pain.
- the herbal compositions of the present invention may be used in dietary supplements and pharmaceutical or veterinary formulations.
- the herb or herbs selected from Tripterygium wilfordii, Ligustrum lucidum and Erycibe schmidtii enhance the joint-rebuilding effect of the glucosamine without introducing any harmful side effects.
- the herb(s) also provide an anti- inflammatory and analgesic effect.
- the glucosamine used in the herbal composition of the present invention may be in any suitable form such as glucosamine sulphate, glucosamine hydrochloride or N-acetyl glucosamine. It may be employed as a dry powder or as a solution or dispersion. Preferably the glucosamine is a pharmaceutical grade that is commercially available,. An example of such a product is available from PharmLine, 41 Bridge Street, Florida, New York, 10921. Pharmaceutical grade glucosamine is standardized to greater than 97% purity.
- the herbs used in the herbal composition of the present invention may be employed in any suitable form, for instance as dried herb or as a herbal extract.
- the whole herb is typically dried and ground to a powder.
- the resulting powder of the or each herb is then conveniently mixed with powdered glucosamine to form a herbal composition of the invention in powder form.
- the powder can be administered directly, for instance by being dispersed in a liquid for human subjects to drink or by being mixed into animal feed for animals, for example cats, to consume.
- the powder can be processed into any other conventional dosage form such as tablets, granules or capsules.
- the extract is prepared by any conventional technique known for the extraction of ingredients from botanical material. Suitable techniques include solvent extraction and supercritical fluid extraction with a liquefied gas such as carbon dioxide. If desired the resulting extract may be dried before being formulated into a herbal composition of the invention, for instance by spray-drying or by freeze-drying (lyophilisation). In that case the dried extract may be mixed with powdered glucosamine to form a powder for direct administration to human or animal subjects, for instance as described above. Alternatively the extract may be used directly without prior drying. The herbs or herb extracts are combined with the glucosamine using any conventional technique that is suitable for ingredients of this type.
- the herbs or herb extracts and the glucosamine are all in dry form they are conveniently mixed together, for instance by hand or by means of a mechanical mixer.
- a mixing procedure of this type may also be suitable if some, but not all, of the components of the herbal composition are in dry form.
- Tripterygium wilfordii extract When Tripterygium wilfordii extract is employed in extract form it is preferably a pharmaceutical grade extract that can be obtained commercially, for example, from the Institute of Medicinal Plant Development, Haiding District, Xibeiwang, Beijing 100094, China, a Chinese manufacturer. Pharmaceutical grade Tripterygium wilfordii extract manufactured in China is standardized for triptolide content of about 0.1 weight percent and contains the full spectrum of diterpenes found in the plant. The pharmaceutical grade extract must pass extensive safety and efficacy procedures. As employed in the practice of the invention, the extract has a minimum triptolide content of about 0.01 to 0.5 percent by weight. Preferably, the minimum triptolide content is about 0.1 percent by weight. It is thought that Tripterygium wilfordii acts by the mechanism depicted in Figure 1 to reduce the expression of cyclooxygenase-2 (COX-2), an enzyme involved in prostaglandin synthesis.
- COX-2 cycl
- Ligustrum lucidum When Ligustrum lucidum is employed in extract form it is preferably a pharmaceutical grade extract that can be obtained commercially, for example, from the Institute of Medicinal Plant Development, Haiding District, Xibeiwang, Beijing 100094, China, a Chinese manufacturer.
- the pharmaceutical grade extract must pass extensive safety and efficacy procedures.
- Pharmaceutical grade Ligustrum lucidum extract manufactured in China is standardized for oleanolic acid content of about 45 percent by weight.
- the Ligustrum lucidum extract used for the present invention preferably has an oleanolic acid content of about 30 to about 70 weight percent, and contains additional triterpenoids such as ursolic acid. More preferably, the extract used for the present compositions and methods has a minimum oleanolic acid content of about 45 percent by weight.
- Ligustrum lucidum contains triterpenes oleanolic and ursolic acids which may provide the anti-inflammatory activity. Ligustrum lucidum can also provide hepatoprotection, antitumor promotion, antihyperlipidemia, antihyperglycemia, and protection against aspirin-induced ulcers.
- Erycibe schmidtii is employed in extract form it is preferably a pharmaceutical grade extract that can be obtained commercially, for example, from the Institute of Medicinal Plant Development, Haiding District, Xibeiwang, Beijing 100094, China, a Chinese manufacturer.
- the pharmaceutical grade extract must pass extensive safety and efficacy procedures.
- Pharmaceutical grade Erycibe schmidtii extract manufactured in China is standardized for scopoletin content of about 0.35 weight percent.
- the extract has a scopoletin content of about 0.25 to about 0.70 percentage by weight. More preferably the extract has a minimum scopoletin content of about 0.35 percent by weight.
- Erycibe schmidtii (Ding Gon Teng) is the major ingredient herb (92% by weight) of the medicated wine called "Feng Liao Xing Feng Shi Die Da Yao Jiu" or "Ding Gong Teng Feng Shi Yao Jiu” (DGT wine).
- the main chemical ingredients of E is the major ingredient herb (92% by weight) of the medicated wine called "Feng Liao Xing Feng Shi Die Da Yao Jiu" or "Ding Gong Teng Feng Shi Yao Jiu” (DGT wine).
- the main chemical ingredients of E is the major ingredient herb (92% by weight)
- schmidtii include scopoletin (the aglycone) and scopolin (the glycoside) which is thought to be responsible for the anti- inflammatory and analgesic activity of the herb.
- the herbal composition of the present invention as described above is typically formulated into a pharmaceutical or veterinary composition or a dietary composition such as a dietary supplement, by a conventional method.
- such compositions may include pharmaceutically, veterinarily or dietetically acceptable carriers or diluents as well as various additives such as other vitamins and minerals and inert ingredients such as talc and magnesium stearate that are standard excipients in the manufacture of tablets, capsules or other dosage forms.
- the finished pharmaceutical or veterinary dosage form may be formulated for any route of administration such as orally, parenterally or topically.
- the pharmaceutically, veterinarily or dietetically acceptable carrier or diluent may be, for example, a solvent, dispersion medium, coating, isotonic or absorption delaying agent, sweetener or the like.
- the carrier may be prepared from a wide range of materials including, but not limited to, diluents, binders and adhesives, lubricants, disintegrants, coloring agents, bulking agents, flavoring agents, sweetening agents and miscellaneous materials such as buffers and adsorbents that may be needed in order to prepare a particular composition.
- the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the present compositions is contemplated.
- talc and magnesium stearate are included in the dietary compositions and/or pharmaceutical compositions of the present invention.
- these components are preferably the Astac Brand 400 USP talc powder and the veritable grade of magnesium stearate.
- Other ingredients to improve the manufacture of this composition as a dietary bar, functional food or pharmaceutical formulation include flavorings, sugars, proteins and/or modified starches, as well as fats and oils.
- the dietary compositions and pharmaceutical and veterinary compositions of the present invention can be formulated into a finished dosage form in any suitable manner known to one of skill in the art.
- the daily dosage takes account of factors such as the age, weight and condition of the patient to be treated.
- a typical daily dosage is about 1500 mg of glucosamine for a human divided into one to three tablets, capsules or chewable bars.
- the daily dose of glucosamine per kg of body weight is approximately 21 mg/kg-day.
- the herbal composition of the invention for instance in the form of a dietary supplement or pharmaceutical composition, is formulated into a capsule or tablet using techniques available to one of skill in the art.
- the recommended daily dose for an adult human or animal would preferably be one to six capsules or tablets.
- the present compositions may also be formulated in any other convenient form, such as an injectable solution or suspension, a spray solution or suspension, a lotion, a gum, a lozenge, a food or snack item.
- Food, snack, gum or lozenge items can include any ingestable ingredient, including sweeteners, flavorings, oils, starches, proteins, fruits or fruit extracts, vegetables or vegetable extracts, grains, animal fats or proteins.
- the present herbal compositions can be formulated into food products such as cereals, snack items such as chips, bars, gum drops, chewable candies or slowly dissolving lozenges.
- the herbal composition of the present invention is also suitably formulated into granules or a powder. In this form it can be readily dispersed in water or other liquid such as tea or a soft drink for human subjects to drink. It can be equally readily mixed into feed for administration to animals such as cattle, cats and dogs.
- the herbal composition of the present invention is administered in an amount sufficient to relieve the symptoms of degenerative joint disease, joint inflammation or arthritis while minimizing adverse side effects.
- a therapeutically effective amount is an amount sufficient to enhance the synthesis of glucosaminoglycans and hyaluronic acid without causing harmful side effects.
- a therapeutically effective amount of the composition is an amount sufficient to reduce the expression or activity of cyclooxygenase-2 without causing harmful side effects. In yet another embodiment, the therapeutically effective amount is an amount sufficient to reduce the inflammatory response without causing harmful side effects.
- a herbal composition of the present dietary invention is formulated to deliver each component in the following amounts: (a) about 15.0 to 25.0 mg glucosamine per kg body weight;
- the herbal composition of the present invention is formulated to deliver each component in the following amounts: a. about 21 mg pharmaceutical grade glucosamine per kg body weight; b. about 1.5 mg Tripterygium wilfordii per kg body weight; c. about 5,0 mg Ligustrum lucidum per kg body weight; and d. about 6.5 mg Erycibe schmidtii per kg body weight.
- a herbal composition of the invention was prepared containing pharmaceutical grade glucosamine, Tripterygium wilfordii, Ligustrum lucidum and Erycibe schmidtii.
- the pharmaceutical grade glucosamine which is standardised to contain no less than 97% glucosamine calculated as glucosamine sulphate, was purchased from PharmLine, USA.
- the three herb extracts were made at the Institute of Medicinal Plant Development, Beijing, China.
- the authentication and quality evaluation of the raw herb material, critical to the production of the standardised herb extracts and the therapeutic effect of the finished product, were achieved by conventional macroscopic and microscopic methods of inspection and authentication involving the application of pharmacognosy, phytochemistry and Chinese Materia Medica. In addition TLC and HPLC profiling were used.
- each extract contained a set amount of selected chemical markers which could be quantified by HPLC.
- the chemical marker contents was 0.1% triptolide in Tripterygium wilfordii extract 45% oleanolic acid in Ligustrum lucidum extract and 0.35% scopoletin in Erycibe schmidtii extract.
- Each extract was standardized.
- the pharmaceutical grade glucosamine was combined with the herb extracts in a defined proportion of each ingredient of Tripterygium wilfordii, Ligustrum lucidum and Erycibe schmidtii to form a herbal composition.
- a phamaceutical composition in tablet dosage form was prepared by formulating the herbal composition prepared according to Example 1 with such tabletting excipients as talc and magnesium stearate such that the following amounts of active ingredients could be delivered per kg body weight per day:
- Example 2 In a clinical study on dogs, the tablet dosage form described in Example 2 was administered daily to a group of dogs (1 tablet per day) observed to be suffering from symptoms of arthritis. Preliminary observations by a veterinarian after a week to ten days indicated that there was an improvement in each animal's condition.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU52310/00A AU5231000A (en) | 1999-06-02 | 2000-06-01 | Combination of glucosamine with herbal extracts of tripterygium, ligustrum and erycibe |
EP00937014A EP1185281A1 (en) | 1999-06-02 | 2000-06-01 | Combination of glucosamine with herbal extracts of tripterygium, ligustrum and erycibe |
MXPA01012390A MXPA01012390A (en) | 1999-06-02 | 2000-06-01 | Combination of glucosamine with herbal extracts of tripterygium, ligustrum and erycibe. |
CA002376008A CA2376008A1 (en) | 1999-06-02 | 2000-06-01 | Combination of glucosamine with herbal extracts of tripterygium, ligustrum and erycibe |
GB0131054A GB2367492A (en) | 1999-06-02 | 2000-06-01 | Combination of glucosamine with herbal extracts of triptergium, ligustrum and erycibe |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13717299P | 1999-06-02 | 1999-06-02 | |
US60/137,172 | 1999-06-02 | ||
US15397799P | 1999-09-14 | 1999-09-14 | |
US60/153,977 | 1999-09-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000074696A1 true WO2000074696A1 (en) | 2000-12-14 |
Family
ID=26834986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2000/002092 WO2000074696A1 (en) | 1999-06-02 | 2000-06-01 | Combination of glucosamine with herbal extracts of tripterygium, ligustrum and erycibe |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1185281A1 (en) |
AU (1) | AU5231000A (en) |
CA (1) | CA2376008A1 (en) |
GB (1) | GB2367492A (en) |
MX (1) | MXPA01012390A (en) |
WO (1) | WO2000074696A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006120009A1 (en) * | 2005-05-13 | 2006-11-16 | Nestec S.A. | Production of glucosamine from plant species |
US7270835B2 (en) | 2001-06-20 | 2007-09-18 | Metaproteomics, Llc | Compositions that treat or inhibit pathological conditions associated with inflammatory response |
US7332185B2 (en) | 2001-06-20 | 2008-02-19 | Metaproteomics, Llc | Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
US7718198B2 (en) | 2001-06-20 | 2010-05-18 | Metaproteomics, Llc | Treatment modalities for autoimmune diseases |
US7722903B2 (en) | 2001-06-20 | 2010-05-25 | Metaproteomics, Llc | Modulation of inflammation by hops fractions and derivatives |
US20120040929A1 (en) * | 2003-11-21 | 2012-02-16 | Nestec S.A. | Food composition comprising glucosamine |
US20120237622A1 (en) * | 2009-11-07 | 2012-09-20 | Prashant Neminath Patil | Herbal milk replacer compositions for calf |
US20120288578A1 (en) * | 2009-11-23 | 2012-11-15 | Prashant Neminath Patil | Herbal calf starter compositions |
US8378090B2 (en) | 2005-05-13 | 2013-02-19 | Nestec S.A. | Production of glucosamine from plant species |
US8663623B2 (en) | 2009-10-12 | 2014-03-04 | Prashant Neminath Patil | Herbal cattle feed supplement compositions for enhancing productivity and quality of milk |
US8846115B2 (en) | 2001-11-13 | 2014-09-30 | Metaproteomics, Inc. | Anti-inflammatory cyclooxygenase inhibitors |
CN104096142A (en) * | 2014-07-16 | 2014-10-15 | 刘斌 | Medicine for treating arthritis and arthralgia |
US20150017268A1 (en) * | 2009-10-12 | 2015-01-15 | Prashant Neminath Patil | Methods for improving milk letting down in milch animals |
CN108567963A (en) * | 2018-06-26 | 2018-09-25 | 苏州科技城医院 | A kind of lopseed composition for treating Osteoarthritis |
US10227368B2 (en) | 2013-11-05 | 2019-03-12 | Nestec S.A. | Generation of glucosamine from plant material |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105961117A (en) * | 2016-05-20 | 2016-09-28 | 芜湖欧标农业发展有限公司 | Cutting propagation method for European Ligustrum ovalisolium |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998013057A1 (en) * | 1996-09-27 | 1998-04-02 | Olsen, Nancy, J. | Steroid receptor binding compositions and steroid-sparing preparations thereof in immunosuppression and inflammation |
EP0852946A2 (en) * | 1996-11-29 | 1998-07-15 | Gianfranco De Paoli Ambrosi | Composition for cosmetic, pharmaceutical or dietetic use based on an amino-sugar and/or a polyhydroxylic acid |
WO1998051302A1 (en) * | 1997-05-15 | 1998-11-19 | University Of Washington | Composition and methods for treating alzheimer's disease and other amyloidoses |
US5972998A (en) * | 1997-05-23 | 1999-10-26 | Hoechst Marion Roussel, Inc. | Triptolide derivatives useful in the treatment of autoimmune diseases |
WO1999059578A1 (en) * | 1998-05-19 | 1999-11-25 | Research Development Foundation | Triterpene compositions and methods for use thereof |
WO2000012483A1 (en) * | 1998-09-02 | 2000-03-09 | Pharmagenesis, Inc. | Triptolide prodrugs having high aqueous solubility |
WO2000030666A1 (en) * | 1998-11-24 | 2000-06-02 | University Of Washington | Composition and methods for inhibiting the formation of brain amyloid deposits |
WO2000033659A1 (en) * | 1998-12-08 | 2000-06-15 | University Of Washington | Compositions for treating alzheimer's disease and other amyloidoses |
-
2000
- 2000-06-01 MX MXPA01012390A patent/MXPA01012390A/en unknown
- 2000-06-01 AU AU52310/00A patent/AU5231000A/en not_active Abandoned
- 2000-06-01 CA CA002376008A patent/CA2376008A1/en not_active Abandoned
- 2000-06-01 WO PCT/GB2000/002092 patent/WO2000074696A1/en not_active Application Discontinuation
- 2000-06-01 GB GB0131054A patent/GB2367492A/en not_active Withdrawn
- 2000-06-01 EP EP00937014A patent/EP1185281A1/en not_active Withdrawn
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998013057A1 (en) * | 1996-09-27 | 1998-04-02 | Olsen, Nancy, J. | Steroid receptor binding compositions and steroid-sparing preparations thereof in immunosuppression and inflammation |
EP0852946A2 (en) * | 1996-11-29 | 1998-07-15 | Gianfranco De Paoli Ambrosi | Composition for cosmetic, pharmaceutical or dietetic use based on an amino-sugar and/or a polyhydroxylic acid |
WO1998051302A1 (en) * | 1997-05-15 | 1998-11-19 | University Of Washington | Composition and methods for treating alzheimer's disease and other amyloidoses |
US5972998A (en) * | 1997-05-23 | 1999-10-26 | Hoechst Marion Roussel, Inc. | Triptolide derivatives useful in the treatment of autoimmune diseases |
WO1999059578A1 (en) * | 1998-05-19 | 1999-11-25 | Research Development Foundation | Triterpene compositions and methods for use thereof |
WO2000012483A1 (en) * | 1998-09-02 | 2000-03-09 | Pharmagenesis, Inc. | Triptolide prodrugs having high aqueous solubility |
WO2000030666A1 (en) * | 1998-11-24 | 2000-06-02 | University Of Washington | Composition and methods for inhibiting the formation of brain amyloid deposits |
WO2000033659A1 (en) * | 1998-12-08 | 2000-06-15 | University Of Washington | Compositions for treating alzheimer's disease and other amyloidoses |
Non-Patent Citations (3)
Title |
---|
CONN D. L. ET AL: "Alternative treatments and rheumatic diseases", BULLETIN ON THE RHEUMATIC DISEASES, vol. 48, no. 7, November 1999 (1999-11-01), pages 1 - 4, XP000961321 * |
RAMGOLAM, V. ET AL: "Traditional chinese medicines as immunosuppresive agents", ANNALS ACADEMY OF MEDICINE, SINGAPORE, vol. 29, no. 1, January 2000 (2000-01-01), pages 11 - 16, XP000961356 * |
TAO X. ET AL.: "The chinese antiinflammatory and immunosuppressive herbal remedy Tripterygium Wilfordii Hook F.", REUMATHIC DISEASE CLINICS OF NORTH AMERICA, vol. 26, no. 1, February 2000 (2000-02-01), pages 29 - 50, XP000961355 * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7270835B2 (en) | 2001-06-20 | 2007-09-18 | Metaproteomics, Llc | Compositions that treat or inhibit pathological conditions associated with inflammatory response |
US7332185B2 (en) | 2001-06-20 | 2008-02-19 | Metaproteomics, Llc | Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
US7431948B2 (en) | 2001-06-20 | 2008-10-07 | Metaproteomics, Llc | Compositions that treat or inhibit pathological conditions associated with inflammatory response |
US7718198B2 (en) | 2001-06-20 | 2010-05-18 | Metaproteomics, Llc | Treatment modalities for autoimmune diseases |
US7722903B2 (en) | 2001-06-20 | 2010-05-25 | Metaproteomics, Llc | Modulation of inflammation by hops fractions and derivatives |
US7919125B2 (en) | 2001-06-20 | 2011-04-05 | Metaproteomics, Llc | Modulation of inflammation by hops fractions and derivatives |
US8846115B2 (en) | 2001-11-13 | 2014-09-30 | Metaproteomics, Inc. | Anti-inflammatory cyclooxygenase inhibitors |
US9393253B2 (en) * | 2003-11-21 | 2016-07-19 | Nestec S.A. | Food composition comprising glucosamine |
US9101639B2 (en) | 2003-11-21 | 2015-08-11 | Nestec S.A. | Food composition comprising glucosamine |
US20120040929A1 (en) * | 2003-11-21 | 2012-02-16 | Nestec S.A. | Food composition comprising glucosamine |
US8378090B2 (en) | 2005-05-13 | 2013-02-19 | Nestec S.A. | Production of glucosamine from plant species |
EA013945B1 (en) * | 2005-05-13 | 2010-08-30 | Нестек С.А. | A process for generating glucosamine from plant species |
WO2006120009A1 (en) * | 2005-05-13 | 2006-11-16 | Nestec S.A. | Production of glucosamine from plant species |
US20080200666A1 (en) * | 2005-05-13 | 2008-08-21 | Nestec S.A. | Production Of Glucosamine From Plant Species |
US8663623B2 (en) | 2009-10-12 | 2014-03-04 | Prashant Neminath Patil | Herbal cattle feed supplement compositions for enhancing productivity and quality of milk |
US9827284B2 (en) | 2009-10-12 | 2017-11-28 | Prashant Neminath Patil | Methods for improving milk letting down in milch animals |
US20150017268A1 (en) * | 2009-10-12 | 2015-01-15 | Prashant Neminath Patil | Methods for improving milk letting down in milch animals |
US8668945B2 (en) * | 2009-11-07 | 2014-03-11 | Prashant Neminath Patil | Herbal milk replacer compositions for calf |
US20120237622A1 (en) * | 2009-11-07 | 2012-09-20 | Prashant Neminath Patil | Herbal milk replacer compositions for calf |
US8663719B2 (en) * | 2009-11-23 | 2014-03-04 | Prashant Neminath Patil | Herbal calf starter compositions |
US20120288578A1 (en) * | 2009-11-23 | 2012-11-15 | Prashant Neminath Patil | Herbal calf starter compositions |
US10227368B2 (en) | 2013-11-05 | 2019-03-12 | Nestec S.A. | Generation of glucosamine from plant material |
CN104096142A (en) * | 2014-07-16 | 2014-10-15 | 刘斌 | Medicine for treating arthritis and arthralgia |
CN108567963A (en) * | 2018-06-26 | 2018-09-25 | 苏州科技城医院 | A kind of lopseed composition for treating Osteoarthritis |
CN108567963B (en) * | 2018-06-26 | 2020-12-04 | 苏州科技城医院 | Tuberculate speranskia herb composition for treating osteoarthritis |
Also Published As
Publication number | Publication date |
---|---|
MXPA01012390A (en) | 2003-10-14 |
CA2376008A1 (en) | 2000-12-14 |
EP1185281A1 (en) | 2002-03-13 |
GB0131054D0 (en) | 2002-02-13 |
GB2367492A (en) | 2002-04-10 |
AU5231000A (en) | 2000-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230017195A1 (en) | Compositions and methods of treating viral infections | |
AU2006232644B2 (en) | Anti-inflammatory formulation | |
EP1185281A1 (en) | Combination of glucosamine with herbal extracts of tripterygium, ligustrum and erycibe | |
EP2224939B1 (en) | Preparations with rosehip extracts, and method of producing rosehip extracts | |
AU2003227438A1 (en) | Compositions for preventing or treating pollenosis, allergic nephritis, atopic dermatitits, asthma or urticaria | |
US8741361B2 (en) | NGNA compositions and methods of use | |
US20190015448A1 (en) | Treatment and Prevention of Bone and Joint Disorders | |
WO2008034316A1 (en) | Compound preparation capable of reducing oxidative stress rapidly and the preparative method thereof | |
EP1609466B1 (en) | Pharmaceutical compositions and uses thereof in the preparation of a medicament and/or food compostion for the treatment of overweight and/or correlated symptoms in humans and mammalian as well as process of preparation | |
Brendler et al. | Devil’s Claw (Harpagophytum procumbens DC) an evidence-based systematic review by the natural standard research collaboration | |
US11039636B2 (en) | Treatment and prevention of bone and joint disorders | |
EP1677627B1 (en) | Dietetic preparation with hyaluronate for treatment of osteoporosis | |
AU5231200A (en) | Formulations containing cranberry fruit, dl-methionine, and chinese herbs | |
CN116940343A (en) | Supplement for arthritis and psoriasis | |
AU2022203588A1 (en) | Composition and methods and uses thereof | |
WO2023150113A1 (en) | Fast acting joint health composition and use thereof | |
Wynn | Ten herbs and nutraceuticals you can't live without. | |
JP2020147514A (en) | Composition containing bile acid and herbal medicine | |
JP2022022617A (en) | Muscle synthesis promoter | |
Jamison | Nutraceuticals for Osteoarthritis | |
CN1105587A (en) | Traditional Chinese medicine synergist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2376008 Country of ref document: CA Ref country code: CA Ref document number: 2376008 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/012390 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 52310/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000937014 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: GB Ref document number: 200131054 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2000937014 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000937014 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |